



Canadian
Cancer Clinical
Trials Network

Canadian Cancer Clinical Trials Network

Quarter Performance Report


Quarter 2 2017/18: July 1 – Sept 30, 2017

Table of Contents

Section A: Progress at Adult Network Sites	2
Section B: Progress at Pediatric Network Sites	12
Section C: Portfolio Efficiency	20
Appendix: Additional Notes	21

Section A: Progress at Adult Network Sites

Objective: To improve patient access to academic clinical trials: a) Improve adult patient recruitment by greater than 50% within four years




Notes:

- 915 patients were recruited to adult Portfolio trials in Quarter 2, 2017/18.
- The Network recruitment target for 2017/2018 is 50% above baseline. The quarterly Network target for 2017/2018 is 918 patients recruited to meet an annual target of 3672 patients recruited. The network is well on track for meeting the Y4 network target.
- Data include adult sites with formal Agreements with 3CTN (N=49).
- The Network target is the target recruitment per year, as defined in the 3CTN business plan. The site target is the target recruitment per year as defined in the Agreement between 3CTN and sites.
- 18 out of 49 adult sites exceeded their quarter baseline and 14 out of 49 adult sites exceeded their quarter target.

Q2 2017/18 progress against quarterly 2016/17 Network target			
	Actual	Target	Difference
Accrual	915	918	-3
% above baseline	150%	150.0%	✓

Figure 2. Number of patients recruited to adult Network sites per region in Q2 2017/18



	Manitoba	Atlantic Canada	Alberta	Quebec	British Columbia	Ontario
■ 2017/18 Quarterly Baseline	25	29	45	137	47	330
■ Y4Q2 Actual	15	17	61	163	50	609

Figure 3. Number of patients recruited to adult Network sites per local-regional node (NCC + NACC) in Q2 2017/18




Figure 4. Progress to quarterly recruitment baseline at adult Network sites per region in Q2 2017/18




Figure 5. Percentage of patients recruited to quarter baseline of adult Network sites per local-regional node (NCC + NACC) in Q2 2017/18





Table 1. Number of patients recruited per adult Network site (by fiscal year)

Network Site	Baseline	Y1* Total	% of Y1 baseline	Y2 Total	% of Y2 baseline	Y3 YTD Total	% of Y3 baseline	Q1 2017	Q2 2017	Y4 YTD Total	% of Y4 baseline
London Regional Cancer Program	186	72	77	171	92%	179	96%	43	54	97	52%
Grand River Regional Cancer Centre	20	12	120	13	65%	43	215%	12	7	19	95%
Windsor Regional Hospital	14	8	114	17	121%	63	450%	9	9	18	129%
Juravinski Cancer Centre	181	110	122	231	128%	247	136%	145	116	261	144%
Niagara Health System	17	4	47	22	129%	13	76%	7	9	16	94%
Cambridge Memorial Hospital	11	2	36	2	18%	5	45%	0	1	1	9%
St. Joseph Healthcare Hamilton*	21	-	-	30	500%	54	257%	14	19	33	157%
Sunnybrook Research Institute	141	113	160	229	162%	398	282%	118	103	221	157%
North York General Hospital	1	3	NA	4	NA	8	800%	2	3	5	500%
Toronto East General Hospital	2	0	0	2	100%	1	50%	1	3	4	200%
Humber River Hospital	1	0	NA	2	NA	1	100%	3	2	5	500%
Princess Margaret Cancer Centre	396	157	79	384	97%	533	135%	135	126	261	66%
Northeast Cancer Centre - Health Sciences North	24	2	17	17	71%	12	50%	2	1	3	13%
Trillium Health Partners	27	5	37	5	19%	51	189%	10	0	10	37%
Thunder Bay Regional Health Sciences Centre	26	2	15	3	12%	46	177%	6	2	8	31%
Southlake Regional Health Centre	10	1	20	15	150%	75	750%	9	12	21	210%
Royal Victoria Hospital	8	8	200	18	225%	58	725%	16	5	21	263%
St. Michael's Hospital	19	4	42	0	0%	27	142%	2	0	2	11%
William Osler Health System	1	0	0	0	0%	29	2900%	0	0	0	0%
Markham Stouffville Hospital	1	0	NA	0	NA	28	2800%	3	2	5	500%
Mount Sinai Hospital*	21	-	-	12	109%	40	190%	0	1	1	5%
The Ottawa Hospital Cancer Centre	132	59	89	238	180%	396	300%	111	105	216	164%
Kingston General Hospital	41	24	117	58	141%	122	298%	22	23	45	110%
Lakeridge Health	22	6	55	26	118%	70	318%	9	6	15	68%
CancerCare Manitoba	99	39	79	72	73%	102	103%	30	15	45	45%

Network Site	Baseline	Y1* Total	% of Y1 baseline	Y2 Total	% of Y2 baseline	Y3 YTD Total	% of Y3 baseline	Q1 2017	Q2 2017	Y4 YTD Total	% of Y4 baseline
Saint John Regional Hospital	37	11	59	16	43%	22	59%	1	5	6	16%
Dr. Everett Chalmers Hospital	1	1	200	0	0%	5	500%	4	2	6	600%
The Moncton Hospital****	-	-	-	-	-	-	-	-	-	0	-
Dr. Léon-Richard Oncology Centre	9	2	44	4	44%	3	33%	1	0	1	11%
Nova Scotia Health Authority	39	4	21	31	79%	48	123%	15	8	23	59%
Cape Breton Cancer Centre*****	-	-	-	-	-	-	-	-	-	-	-
PEI Cancer Treatment Centre	8	1	25	8	100%	2	25%	0	0	0	0%
Nova Scotia Health Authority, Hematology	7	12	343	25	357%	16	229%	4	2	6	86%
Eastern Regional Health Authority (NFL)	15	0		0		12	80%	2	0	2	13%
BC Cancer Agency - Vancouver Centre	106	67	126	117	110%	150	142%	44	27	71	67%
Abbotsford Centre	16	10	125	28	175%	13	81%	5	3	8	50%
Centre for the North, Prince George	1	2	400	6	600%	4	400%	6	0	6	600%
Sindi Ahluwalia Hawkins Centre for the Southern Interior	38	27	142	38	100%	30	79%	10	5	15	39%
Vancouver Island Centre	26	9	69	44	169%	69	265%	27	15	42	162%
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal(CIUSSS CODIM)*	87	0	-	72	164%	150	172%	55	18	73	84%
CISSS de l'Outaouais*	3	0	-	0	0%	4	133%	17	7	24	800%
CHU de Québec – Université Laval*	180	0	-	25	28%	144	80%	78	59	137	76%
CISSS du Bas-Saint-Laurent(CISSS-BSL)*	4	0	-	0	0%	4	100%	1	2	3	75%
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS-Estrie-CHUS)*	46	0	-	16	70%	70	152%	11	23	34	74%
Centre Hospitalier de l'Université de Montréal (CHUM)*	153	0	-	59	77%	123	80%	53	30	83	54%
CIUSSS de la Mauricie-et-du-Centre-du-Québec (CIUSSS MCQ) *	8	0	-	1	25%	17	213%	4	6	10	125%
CISSS de Laval*	4	0	-	3	150%	12	300%	5	2	7	175%
CIUSSS du Nord-de-l'Île-de-Montréal(CIUSSS NDIM)*	3	0	-	0	0%	4	133%	2	0	2	67%
CIUSSS de l'Est-de-l'Île-de-Montréal(CIUSSS-EDIM)*	60	0	-	12	40%	51	85%	8	16	24	40%
Tom Baker Cancer Centre	76	41	108	140	184%	125	164%	36	34	70	92%
Cross Cancer Institute	102	50	98	112	110%	137	134%	16	27	43	42%
Adult Patient Sites (N=49 for Y3, 48 for Y2, and 36 for Y1)	2451	868	94	2328	109%	3816	156%	1114	915	2029	83%

Objective: To demonstrate impact of the Network and academic trials on the Canadian Health Care System: a) Develop and maintain a portfolio of academic trials that will ensure the enthusiastic participation of academic trialists and patients and impact patient care.


Figure 6. Total Portfolio trials at adult Network sites per quarter, Q4 2014/15 - Q2 2017/18



Notes:


- There were 176 Portfolio trials up to this quarter 2017 for adult sites, (YTD Total =1 newly added+2 closed YTD +173 previous recruiting trials)
- 1 new trial is included in the 174 recruiting trials at the end of Quarter 2
- Three trials were available at both adult and pediatric Network sites in fiscal year 2017 and are included in both adult and pediatric figures

Figure 7. Breakdown of 2017 Fiscal Year Portfolio trials at adult Network sites



- The data provided in Figure 7 are a snapshot of the Portfolio as of Dec. 22, 2017 (N=176)

Figure 8. Breakdown of personalized medicine trials at adult Network sites for 2017/2018 Portfolio Trials




Notes:

- 70 Personalized medicine trials open to recruitment at adult Network sites, as of Dec. 20, 2017 (n=176)
- 40% of all trials at adult Network sites have a personalized medicine component
- Three trials were available at both adult and pediatric Network sites in fiscal year 2017 and are included in both adult and pediatric figures
- There were 25 out of 176 (14%) immunotherapy related trials.

Category	Definition
Patient eligibility	Use of a genetic marker or other individualized biologic factor to determine if patient is eligible for the trial (i.e. included in trial design via the inclusion/exclusion criteria)
Study endpoint	Use of a genetic marker or other individualized biologic factor to correlate with study endpoint (i.e. included in trial design as an objective or endpoint)
Stratify into different groups	After patient enrollment, trial design uses a genetic marker or other individualized biologic factor to stratify into different groups (i.e. included in trial design to stratify for treatment or analysis groups)
Targeted therapy	Trial is using a molecular targeted therapy; drug used in a “targeted” patient population (i.e. HER2+ breast cancer gets a HER2 targeted agent)

Figure 9. Breakdown of portfolio trials at adult Network sites for 2017/2018 Portfolio Trials by lead country




Notes:

- Breakdown of trials at adult Network sites by lead country, as of Dec. 20, 2017 (n=176)
- Approx. 67% of all trials at adult Network sites are led by Canada – 7% of which are international, multicentered studies
- The average number of adult Network sites per trial is 6.14.
- Three trials were available at both adult and pediatric Network sites in 2017/2018 and are included in both adult and pediatric figures

Section B: Progress at Pediatric Network Sites

Objective: To improve patient access to academic clinical trials: Improve recruitment of pediatric patients



Notes:

- 90 patients were recruited to Portfolio trials at pediatric Network sites in Quarter 2 2017/18. The quarterly target for 2017/18 is 130 patients recruited to meet an annual target of 521 patients recruited. Pediatric Network sites are 27% below its quarterly target for recruitment
- Data includes pediatric sites associated with the C17 Council (N=17)

	Accrual	Target	Difference
Accrual	90	130	40
% above baseline	103%	130%	🚩

Figure 11. Number of patients recruited per pediatric Network site in Q2 2017/18




Figure 12. Progress to quarter baseline recruitment per pediatric Network site in Q2 2017/18





Table 2. Number of patients recruited per pediatric Network site (by fiscal year)

Network Site	Baseline	Y1* Total	% of Y1 baseline	Y2 Total	% of Y2 baseline	Y3 YTD Total	% of Y3 baseline	Q1 2017	Q2 2017	Y4 YTD Total	% of Y4 baseline
C17 (national pediatric total)	347	164	95	358	103%	355	102%	105	90	195	56%
The Hospital for Sick Children	91	50	110	109	120%	89	98%	21	17	38	42%
CHU Sainte-Justine, peds	42	18	86	26	62%	44	105%	8	9	17	40%
BC Children's Hospital	34	13	76	46	135%	41	121%	13	10	23	68%
Montreal Children's Hospital	24	9	75	23	96%	14	58%	8	6	14	58%
Alberta Children's Hospital	21	10	95	21	100%	10	48%	3	8	11	52%
McMaster/Hamilton Health Sciences Centre	14	6	86	20	143%	19	136%	11	6	17	121%
Children's Hospital of Eastern Ontario	20	10	100	18	90%	35	175%	9	8	17	85%
Children's Hospital, London Health Sciences Centre	12	7	117	15	125%	26	217%	3	3	6	50%
Stollery Children's Hospital	11	8	145	10	91%	26	236%	8	5	13	118%
IWK Health Centre	20	6	60	20	100%	16	80%	10	5	15	75%
CHU de Quebec, peds	17	7	82	14	82%	7	41%	1	8	9	53%
CancerCare Manitoba, peds	18	5	56	20	111%	14	78%	8	1	9	50%
Saskatoon Cancer Centre	6	9	300	6	100%	5	83%	1	0	1	17%
Janeway Child Health Centre	4	1	50	3	75%	4	100%	1	0	1	25%
Kingston General Hospital	9	5	111	7	78%	5	56%	0	4	4	44%
Allan Blair Cancer Centre, peds	4	0	0	0	0%	0	0%	0	0	0	0%
CHU de Sherbrooke, peds	1	0	NA	0	NA	0	0%	0	0	0	0%
Ped sites (N=17) total	347	164	95%	358	103%	355	102%	105	90	195	56%

Objective: To demonstrate impact of the Network and academic trials on the Canadian Health Care System: a) Develop and maintain a portfolio of academic trials that will ensure the enthusiastic participation of academic trialists and patients and impact patient care.

**Figure 13. Total Portfolio trials at pediatric Network sites per quarter
Q4 2014/15 - Q2 2017/18**



Notes:

- There were 41 Portfolio trials available at pediatric Network sites, 4 new trial added at the end of Quarter 2 2017/2018.
- The data provided in Figure 13 is a snapshot of the Portfolio as of Dec. 20, 2017.
- Three trials were available at both adult and pediatric Network sites in 2017/18 and is included in both adult and pediatric figures.

Figure 14. Breakdown of Fiscal 2017 Portfolio trials at pediatric Network sites





Figure 15. Breakdown of personalized medicine trials at pediatric Network sites in fiscal year 2017/2018




Notes:

- 23 Personalized medicine trials at pediatric Network sites, as of Dec. 20, 2017 (n=41)
- 56% of all trials at pediatric Network sites have a personalized medicine component
- Three trials were available at both adult and pediatric Network sites in 2017 and are included in both adult and pediatric figures
- There were 8 out of 40 trials (25%) that were immunotherapy related trials.

Category	Definition
Patient eligibility	Use of a genetic marker or other individualized biologic factor to determine if patient is eligible for the trial (i.e. included in trial design via the inclusion/exclusion criteria)
Study endpoint	Use of a genetic marker or other individualized biologic factor to correlate with study endpoint (i.e. included in trial design as an objective or endpoint)
Stratify into different groups	After patient enrollment, trial design uses a genetic marker or other individualized biologic factor to stratify into different groups (i.e. included in trial design to stratify for treatment or analysis groups)
Targeted therapy	Trial is using a molecular targeted therapy; drug used in a “targeted” patient population (i.e. HER2+ breast cancer gets a HER2 targeted agent)

Figure 16. Breakdown of Portfolio trials at pediatric Network centres by lead country, in 2017/2018



Notes:

- Breakdown of trials at pediatric Network sites by lead country, as of Dec. 22, 2017 (n=41)
- 25% of all trials at pediatric Network sites are led by Canada – 5% of which are international, multicentered studies
- The average number of Network sites per trial is **8.22**.
- Three trials were available at both adult and pediatric Network sites in 2017-2018 and are included in both adult and pediatric figures

Section C: Portfolio Efficiency

Objective: To improve patient access and increase in successful completion of trials

Portfolio approval process timeline:

Calendar Year	# Application Completed	Average Application Processing Time (days)
2015	89	24
2016	70	24
2017	44	15

Calendar Year	# Application Completed	Average FPR Time (days)
2015	6	47
2016	10	98
2017	1	71

Note: 1) from application received to approve/decline of the application since Jan 13, 2015 to September 18, 2017; 2) from date site agreed to pursue peer review to date last reviewer submitted completed peer review package to 3CTN (approved as peer reviewed).

Appendix: Additional Notes

Table 3. Reporting periods and dates Q4 2014/15 – Q2 2017/18

Quarter	Period	Recruitment Database Lock
Q3 2014/15	October – December 2014	NA*
Q4 2014/15	January – March 2015	NA*
Q1 2015/16	April – June 2015	NA*
Q2 2015/16	July – September 2015	October 20, 2015
Q3 2015/16	October – December 2015	March 31, 2016
Q4 2015/16	January – March 2016	May 31, 2106
Q1 2016/17	April – June 2016	August 31, 2016
Q2 2016/17	July – September 2016	November 15, 2016
Q3 2016/17	October – December 2016	February 15, 2017
Q4 2016/17	January – March 2017	May 31, 2107
Q1 2017/18	April – June 2017	August 31, 2017
Q2 2017/18	July – September 2017	September 30, 2017

*Dates not available as database lock implemented in Q2 2015/16

***Other metrics such as site efficiency related are reported on yearly basis